EA1181 COMPASS: Preoperative THP and Postoperative HP in Patients with HER2-Positive Breast Cancer Who Achieve a Pathologic Complete Response (H-47929)

This study is being done to find out if patients with HER2-positive breast cancer who have no cancer remaining at surgery after 12 weeks of chemotherapy (paclitaxel or docetaxel) and two HER2-targeted therapies (pertuzumab and trastuzumab) can avoid further chemotherapy after surgery. Patients who have no remaining cancer at surgery will continue treatment with the two HER2-targeted treatments without chemotherapy.